Effect of Intensive Therapy on Residual β-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications Trial
Journal: Annals of Internal Medicine (1998)

Articles1 April 1998Effect of Intensive Therapy on Residual β-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications TrialA Randomized, Controlled TrialAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-7-199804010-00001 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractBackground:Although insulin secretion is severely decreased in most patients with type 1 diabetes, levels of residual insulin secretion often vary early in the disease. The significance of residual insulin secretion with regard to metabolic control and to long-term complications and ways to preserve such secretion are not well understood.Objective:To compare the effects of intensive and conventional therapy on residual insulin secretion in Diabetes Control and Complications Trial (DCCT) participants.Design:Multicenter, randomized, controlled clinical trial.Setting:29 DCCT clinical centers.Patients:855 of the 1441 DCCT participants had had type 1 diabetes for 1 to 5 years at baseline. Of these 855 patients, 303 were C-peptide responders (C-peptide level, 0.20 to 0.50 pmol/mL after ingestion of a standardized, mixed meal); 138 of these patients were randomly assigned to intensive therapy, and 165 were assigned to conventional therapy. Five hundred fifty-two patients were nonresponders (stimulated C-peptide level < 0.2 pmol/mL); 274 of these patients were assigned to intensive therapy, and 278 were assigned to conventional therapy.Interventions:1] Intensive therapy with 3 or more insulin injections daily or continuous subcutaneous infusion of insulin, guided by 4 or more glucose tests per day or 2) conventional therapy with 1 or 2 insulin injections daily.Measurements:Stimulated C-peptide level was measured annually in responders. Development of retinopathy and microalbuminuria was assessed annually, hemoglobin A1c levels were measured quarterly, and episodes of hypoglycemia were ascertained quarterly.Results:Responders receiving intensive therapy maintained a higher stimulated C-peptide level and a lower likelihood of becoming nonresponders than did responders receiving conventional therapy (risk reduction, 57% [95% CI, 39% to 71%]; P < 0.001). As in the entire DCCT cohort, intensively treated responders had a reduced risk for retinopathy progression and development of microalbuminuria and a higher risk for severe hypoglycemia compared with conventionally treated responders. Among intensively treated patients, responders had a lower hemoglobin A1c value (P < 0.01), a 50% (95% CI, 12% to 72%) reduced risk for retinopathy progression, and a lower risk for severe hypoglycemia (risk reduction, 65% [CI, 53% to 74%]; P < 0.001) compared with nonresponders.Conclusions:Intensive therapy for type 1 diabetes helps sustain endogenous insulin secretion, which, in turn, is associated with better metabolic control and lower risk for hypoglycemia and chronic complications. These observations underscore the importance of initiating intensive diabetic management as early as safely possible after type 1 diabetes is diagnosed.References1. Ludvigsson J, Heding LG. Beta-cell function in children with diabetes. Diabetes. 1978; 27(Suppl 1):230-4. Google Scholar2. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C. Effect of strict blood glucose control on residual β-cell function in insulin-dependent diabetics. Diabetologia. 1981; 20:530-4. Google Scholar3. Krarup T, Madsbad S. Effect of two periods with intensified insulin treatment on B-cell function during the first 18 months of type 1 (insulin-dependent) diabetes mellitus. Diabete Metab. 1986; 12:256-60. Google Scholar4. de Beaufort CE, Bruining GJ, Aarsen RS, den Boer NC, Grose WF. Does continuous subcutaneous insulin infusion (CSII) prolong the remission phase of insulin-dependent diabetic children? Preliminary findings of a randomized prospective study. Neth J Med. 1985; 28:53-4. Google Scholar5. Bergenstal RM, Dupre J, Lawson PM, Rubenstein AH. Observations on C-peptide and free insulin in the blood during continuous subcutaneous insulin infusion and conventional insulin therapy. Diabetes. 1985; 34(Suppl 3):31-6. Google Scholar6. Perlman K, Ehrlich RM, Filler RM, Albisser AM. Sustained normoglycemia in newly diagnosed type I diabetic subjects. Short-term effects and one-year follow-up. Diabetes. 1984; 33:995-1001. Google Scholar7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329:977-86. Google Scholar8. The Diabetes Control, and Complications trial (DCCT). Design and methodological considerations for the feasibility phase. The DCCT Research Group. Diabetes. 1986; 35:530-45. Google Scholar9. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observation during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab. 1987; 65:30-6. Google Scholar10. Steffes M, Tamborlane W, Becker D, Palmer J, Cleary P. The effect of intensive diabetes treatment on residual β cell function in the Diabetes Control and Complications Trial (DCCT) [Abstract]. Diabetes. 1996; 46(Suppl 2):18A. Google Scholar11. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995; 18:361-76. Google Scholar12. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial (DCCT): a multicenter study. The DCCT Research Group. Clin Chem. 1987; 33:2267-71. Google Scholar13. Wei LJ, Lachin JM. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. Journal of the American Statistical Association. 1984; 79:653-61. Google Scholar14. Lee ET. Statistical Methods for Survival Data Analysis. Belmont, CA: Lifetime Learning; 1980; 88-92, 127-9. Google Scholar15. McCullagh P, Nelder JA. Generalized Linear Models. 2d ed. New York: Chapman & Hall; 1989:194-200, 429-30. Google Scholar16. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995; 44:968-83. Google Scholar17. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995; 47:1703-20. Google Scholar18. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996; 45:1289-98. Google Scholar19. Leahy JC. Natural history of β-cell dysfunction. Diabetes Care. 1990; 13:992-1010. Google Scholar20. Kernell A, Ludvigsson J, Finnstrom K. Vitreous fluorophotometry in juvenile diabetics with and without retinopathy in relation to metabolic control: insulin antibodies and c-peptide levels. Acta Ophthalmol (Copenh). 1990; 68:415-20. Google Scholar21. Wahren J, Johansson BL, Wallberg-Henriksson H, Linde B, Fernqvist-Forbes E, Zierath JR. C-peptide revisited-new physiological effects and therapeutic implications. J Intern Med. 1996; 240:115-24. Google Scholar22. Wahren J, Johansson BL, Wallberg-Henriksson H. Does C-peptide have a physiological role? Diabetologia. 1994; 37(Suppl 2):S99-107. Google Scholar23. Madsbad S, Lauritzen E, Faber OK, Binder C. The effect of residual β-cell function on the development of diabetic retinopathy. Diabet Med. 1986; 3:42-5. Google Scholar Author, Article, and Disclosure InformationAffiliations: Grant Support: In part by the Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, through cooperative agreements and a research contract. Additional support was given by the National Heart, Lung and Blood Institute; the National Eye Institute; and the National Center for Research Resources.Corresponding Author: The DCCT Research Group, Box NDIC/DCCT, Bethesda, MD 20892. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPredicting endocrine function after total pancreatectomy and islet cell autotransplantation: A novel approach utilizing computed tomography texture analysisInfluence of the occurrence and duration of partial remission on short-term metabolic control in type 1 diabetes: the DIABHONEY pediatric studyThe Relationship Between Long-Term Glycemic Control and Partial Remission in Type 1 Diabetes: A Retrospective StudyExploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetesISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoringThe continuous spectrum of glycaemic variability changes with pancreatic islet function: A multicentre cross‐sectional study in ChinaTotal pancreatectomy and islet cell autotransplantation: a 10-year update on outcomes and assessment of long-term durabilityHigher risk of severe hypoglycemia in children and adolescents with a rapid loss of C-peptide during the first 6 years after type 1 diabetes diagnosisGlycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic reviewC‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspectiveCLOuDs Disperse — Top-Notch Glucose Control and Residual C-Peptide SecretionClosed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 DiabetesIntraportal Islet Autotransplantation Independently Improves Quality of Life After Total Pancreatectomy in Patients With Chronic Refractory PancreatitisIntralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2Association between treatment effect on C‐peptide preservation and HbA1c in meta‐analysis of glutamic acid decarboxylase (GAD)‐alum immunotherapy in recent‐onset type 1 diabetesA pragmatic real‐world trial examining the impact of an alteration of prescribing practice at diagnosis in paediatric type 1 diabetes mellitusC-peptide levels and the prevalence of islets autoantibodies in children with type 1 diabetes mellitus with different duration of the diseaseComplications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose MonitoringHigh Residual β-cell Function in Chinese Patients With Autoimmune Type 1 DiabetesPreservation of C-Peptide Levels in Children with New-Onset Type 1 Diabetes: A Comparison Based on Body Mass IndexInsulin Requirement and Complications Associated With Serum C-Peptide Decline in Patients With Type 1 Diabetes Mellitus During 15 Years After DiagnosisInterleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectivesPostinitial remission in children with type 1 diabetes mellitusKann eine optimale Blutzuckereinstellung bei einem neu entdeckten Typ 1 Diabetes eine Verbesserung der β-Zell-Funktion erreichen? Eine Metaanalyse der dazu vorliegenden InterventionenImpact of flash glucose monitoring on glycemic control varies with the age and residual β ‐cell function of patients with type 1 diabetes mellitusChanges of insulin resistance status and development of complications in type 1 diabetes mellitus: Analysis of DCCT/EDIC studyLong-term β-cells autoimmune destruction markers persistence and residual C-peptide secretion in type 1 diabetes mellitusInsulin TherapyThe heterogeneity of type 1 diabetes: From immunopathology to immune interventionA systematic review and meta‐analysis of interventions to preserve insulin‐secreting β‐cell function in people newly diagnosed with type 1 diabetes: Results from intervention studies aimed at improving glucose controlErgocalciferol in New-onset Type 1 Diabetes: A Randomized Controlled TrialHow to Screen Appropriately for Monogenic DiabetesDiagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine eraCan the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case ReportMeasurement of Peak C-Peptide at Diagnosis Informs Glycemic Control but not Hypoglycemia in Adults With Type 1 Diabetesβ‐Cell failure in diabetes: Common susceptibility and mechanisms shared between type 1 and type 2 diabetesResidual C-peptide secretion and hypoglycemia awareness in people with type 1 diabetesEvaluating the antidiabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse modelsResidual β-Cell Function in Type 1 Diabetes Followed for 2 Years after 3C StudyC-peptide enhances glucagon secretion in response to hyperinsulinemia under euglycemic and hypoglycemic conditionsCombination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetesA Strategy to Simultaneously Cure Type 1 Diabetes and Diabetic Nephropathy by Transplant of Composite Islet-Kidney GraftsRealising the long-term promise of insulin therapy: the DCCT/EDIC studyGlucagon stimulation test as a possible predictor of residual β‐cell functionAdipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patientsThe Effects of Dietary Nutrition Intake on Glycemic Variability in Type 1 Diabetes Mellitus AdultsAnti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trialSurrogate markers and predictors of endogenous insulin secretion in children and adolescents with type 1 diabetesResidual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemiaA little help from residual β cells has long-lasting clinical benefitsClinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular ComplicationsRapamycin Plus Vildagliptin to Recover β-Cell Function in Long-Standing Type 1 Diabetes: A Double-Blind, Randomized TrialProinsulin‐specific T‐cell responses correlate with estimated c‐peptide and predict partial remission duration in type 1 diabetesDiabetes MellitusFasting parameters for estimation of stimulated β cell function in islet transplant recipients with or without basal insulin treatmentUpdate on clinical screening of maturity-onset diabetes of the young (MODY)The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes DiagnosisSodium–glucose cotransporter 2 inhibitors improved time‐in‐range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single‐center, pilot studyAutocrine C‐peptide protects INS1 β cells against palmitic acid‐induced oxidative stress in peroxisomes by inducing catalaseRandomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 DiabetesPreserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetesHigh residual C-peptide likely contributes to glycemic control in type 1 diabetesAssessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocolThe remission phase in type 1 diabetes: Changing epidemiology, definitions, and emerging immuno‐metabolic mechanismsTargeted pharmacological therapy restores β-cell function for diabetes remissionUK’s nationally funded integrated islet transplant programEfficacy and safety of long-term insulin pump treatment in patients with type 1 diabetes aged over 50 yearsThe impact of type 1 diabetes mellitus on male sexual functions and sex hormone levelsPredictors of Recurrent Severe Hypoglycemia in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia During the HypoCOMPaSS StudyManganese-enhanced MRI: Comparison of agents in the rat pancreasNeratinib protects pancreatic beta cells in diabetesA Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Alpha-1 Antitrypsin (AAT) (Glassia®) in the Treatment of Recent-Onset Type 1 DiabetesLower Insulin-Dose Adjusted A1c (IDAA1c) Is Associated With Less Complications in Individuals With Type 1 Diabetes Treated With Hematopoetic Stem-Cell Transplantation and Conventional TherapyPatient Perception and Satisfaction With Insulin Pump System: Pilot User Experience SurveyPrognosis for residual islet β‐cell secretion function in young patients with newly diagnosed type 1 diabetesOptimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and RecommendationsPersistent C‐peptide is associated with reduced hypoglycaemia but not HbA 1c in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 yearsDiabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: The SEARCH for diabetes in youth studyCapturing residual beta cell function in type 1 diabetesCharacteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapyPlasma lipid species at type 1 diabetes onset predict residual beta-cell function after 6 monthsInsulin therapy for type 2 diabetes – are we there yet? The d-Nav® storyGlycemic variability in the development of cardiovascular complications in diabetesInnate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetesISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescentsBeta cell function after intensive subcutaneous insulin therapy or intravenous insulin infusion at onset of type 1 diabetes in children without ketoacidosisFrequent Monitoring of C-Peptide Levels in Newly Diagnosed Type 1 Subjects Using Dried Blood Spots Collected at HomeVerapamil and beta cell function in adults with recent-onset type 1 diabetesBeta cell preservation in patients with type 1 diabetesAlpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokineticsExploring C-peptide loss in type 1 diabetes using growth curve analysisDefining outcomes for beta cell replacement therapy: a work in progressNew Horizons in the Treatment of Type 1 Diabetes: More Intense Immunosuppression and Beta Cell ReplacementMeta-genome-wide association studies identify a locus on chromosome 1 and multiple variants in the MHC region for serum C-peptide in type 1 diabetesAmeliorative effects of taurine against diabetes: a reviewAre we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemiaNovel blood glucose lowering therapies for managing type 1 diabetes in paediatric patientsA Role for Total Pancreatectomy and Islet Autotransplant in the Treatment of Chronic PancreatitisNormal meal tolerance test is preferable to the glucagon stimulation test in patients with type 2 diabetes that are not in a hyperglycemic state: Comparison with the change of C-peptide immunoreactivityKetoacidosis at onset of type 1 diabetes is a predictor of long-term glycemic controlPresymptomatic screening for autoimmune β-cell disorder: Baby steps toward prevention?Total Pancreatectomy With Islet Autotransplantation for Acute Recurrent and Chronic PancreatitisC-peptide levels and the risk of diabetes and pre-diabetes among Chinese women with gestational diabetesCoincidence of PTPN22 c.1858CC and FCRL3 -169CC genotypes as a biomarker of preserved residual β-cell function in children with type 1 diabetesIncreased Effector Memory Insulin-Specific CD4+ T Cells Correlate With Insulin Autoantibodies in Patients With Recent-Onset Type 1 DiabetesEarly prediction of autoimmune (type 1) diabetesEffectiveness of MiniMed 640G with SmartGuard® System for prevention of hypoglycemia in pediatric patients with type 1 diabetes mellitusEfectividad del sistema MiniMed 640G con SmartGuard® para la prevención de hipoglucemia en pacientes pediátricos con diabetes mellitus tipo 1Diabètes post-transplantation rénaleInsulin and Immunotherapy in Children and Adolescents with Type 1 DiabetesC-peptide antioxidant adaptive pathways in β cells and diabetesActive Subjects with Autoimmune Type 1 Diabetes have Better Metabolic Profiles than Sedentary ControlsFactors Associated with C-peptide Levels after Diagnosis in Children with Type 1 Diabetes MellitusClinical and Metabolic Characteristics among Mexican Children with Different Types of Diabetes MellitusIslet TransplantationDouble-diabetes in a real-world sample of 2711 individuals: associated with insulin treatment or part of the heterogeneity of type 1 diabetes?T‐cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseasesImmune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 DiabetesFall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin DoseDiabetes mellitus in childhood: an emerging condition in the 21st centuryStrategies for clinical trials in type 1 diabetesRevisiting multiple models of progression of β-cell loss of function in type 1 diabetes: Significance for prevention and cureIntensive glucose control versus conventional glucose control for type 1 diabetes mellitusRelation entre taux de peptide C après transplantation de cellules d’îlots et paramètres du contrôle glycémiqueCorrelation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL TrialResting beta-cells – A functional reserve?Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetesC-peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic RegistryResidual β-Cell Function Predicts Clinical Response After Autologous Hematopoietic Stem Cell TransplantationPancreatic β Cell Mass DeathAssociations of demographic and behavioural factors with glycaemic control in young adults with type 1 diabetes mellitusThe Pathobiology of Diabetes MellitusInsulin SecretionType 1 (Insulin-Dependent) Diabetes MellitusBeta Cell Transplantation and RegenerationKetoacidosis at diagnosis in childhood-onset diabetes and the risk of retinopathy 20years laterIssues in Diagnosis and Treatment of Type 1 Diabetes Mellitus in ChildhoodFactors associated with early beginning of partial remission in young adult patients with newly diagnosed type 1 diabetesPredictive factors for prolonged remission after autologous hematopoietic stem cell transplantation in young patients with type 1 diabetes mellitusInfluence of remission and its duration on development of early microvascular complications in young adults with type 1 diabetesContinuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetesFactors Predicting Outcomes After a Total Pancreatectomy and Islet Autotransplantation Lessons Learned From Over 500 CasesStaging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes AssociationComparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the CommunityBeta-cell destruction and preservation in childhood and adult onset type 1 diabetesDisease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Evidence for Residual and Partly Reparable Insulin Secretory Function and Maintained β-Cell Gene Expression in Islets From Patients With Type 1 DiabetesCGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetesExome sequencing identifies novel ApoB loss-of-function mutations causing hypobetalipoproteinemia in type 1 diabetesUnraveling the contribution of pancreatic beta-cell suicide in autoimmune type 1 diabetesAdolescent non-adherence reveals a genetic cause for diabetesCombination immunotherapies for type 1 diabetes mellitusEpidemiology and risk factors for type 1 diabetes mellitusPancreatic morphology in normal and diabetic statesMost People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin MicrosecretorsDemonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet TransplantationProgressive β Cell Failure in Type 2 Diabetes Mellitus: Microvascular Pancreatic Isletopathy?Preserved C-peptide levels in overweight or obese compared with underweight children upon diagnosis of type 1 diabetes mellitusPossible Contribution of Taurine to Distorted Glucagon Secretion in Intra-Islet Insulin Deficiency: A Metabolome Analysis Using a Novel α-Cell Model of Insulin-Deficient DiabetesThe Effectiveness and Durability of an Early Insulin Pump Therapy in Children and Adolescents with Type 1 Diabetes MellitusPartial Remission Definition: Validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish Children with New-Onset Type 1 DiabetesMig6 haploinsufficiency protects mice against streptozotocin-induced diabetesLong-Term Outcomes After Total Pancreatectomy and Islet Cell AutotransplantationInsulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot studyLow-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 DiabetesNon-immune-based treatment for type 1 diabetes: the way to go?Phases of type 1 diabetes in children and adolescentsDisease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yrGAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 monthsFactors determining insulin requirements in women with type 1 diabetes mellitus during pregnancy: a reviewDipeptidyl Peptidase 4 Inhibitor Sitagliptin Maintains β-Cell Function in Patients With Recent-Onset Latent Autoimmune Diabetes in Adults: One Year Prospective StudyTreatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 TrialEvaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed MealGenetic and Epigenetic Instability of Stem CellsNon-antigenic and antigenic interventions in type 1 diabetesCritical mass in diabetesCostimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of TreatmentAge-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal studyResidual C-peptide in type 1 diabetes: what do we really know?Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low GlucoseCharacterization of residual β cell function in long-standing type 1 diabetesImpact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications TrialB-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year ResultsPeripartum Management of Glycemia in Women With Type 1 DiabetesManagement of Type 1 Diabetes in Older AdultsTherapy with InsulinThe majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cellsCharacteristics and Determinants of Partial Remission in Children with Type 1 Diabetes Using the Insulin-Dose-Adjusted A1C DefinitionThe Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Summary and Future DirectionsGLP-1 agonists in type 1 diabetesAnti-CD3 clinical trials in type 1 diabetes mellitusDeoxyhypusine Synthase Promotes Differentiation and Proliferation of T Helper Type 1 (Th1) Cells in Autoimmune DiabetesExercise to preserve beta cell function in recent-onset type 1 diabetes mellitus (EXTOD) - a study protocol for a pilot randomized controlled trialDiabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and ContributionsCelebrating 30 Years of Research Accomplishments of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications StudyEffectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 DiabetesInmunoterapia en diabetes mellitus tipo 1. ¿Quo vadis?Urinary C‐peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetesFactors associated with diabetic ketoacidosis at onset of Type 1 diabetes in children and adolescentsTeplizumab Preser